dc.creator | Rodrigues, Rosana Souza | |
dc.creator | Ribeiro, Gabriel Motta | |
dc.creator | Barreto, Miriam Menna | |
dc.creator | Zin, Walter Araujo | |
dc.creator | Mendes, Júlia de Toledo | |
dc.creator | Martins, Philippe Alcantara G. | |
dc.creator | Almeida, Sergio Altino de | |
dc.creator | Basílio, Rodrigo | |
dc.creator | Gonçalves, Remy Martins | |
dc.creator | Hotz, Eugênio Damaceno | |
dc.creator | Bozza, Patricia T. | |
dc.creator | Bozza, Fernando A. | |
dc.creator | Carvalho, Alysson Roncally Silva | |
dc.creator | Castro, Paulo Henrique Rosado de | |
dc.date | 2022-12-04T20:59:16Z | |
dc.date | 2022-12-04T20:59:16Z | |
dc.date | 2022 | |
dc.date.accessioned | 2023-09-26T23:56:54Z | |
dc.date.available | 2023-09-26T23:56:54Z | |
dc.identifier | RODRIGUES, Rosana Souza et al. Increased Lung Immune Metabolic Activity in COVID-19 Survivors. Clinical Nuclear Medicine, v. 47, n. 12, p. 1 - 7, Dec. 2022. | |
dc.identifier | 1536-0229 | |
dc.identifier | https://www.arca.fiocruz.br/handle/icict/55889 | |
dc.identifier | 10.1097/RLU.0000000000004376 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8895892 | |
dc.description | Purpose: We quantified lung glycolytic metabolic activity, clinical symptoms
and inflammation, coagulation, and endothelial activation biomarkers
in 2019 coronavirus disease (COVID-19) pneumonia survivors.
Methods: Adults previously hospitalized with moderate to severe COVID-19
pneumonia were prospectively included. Subjects filled out a questionnaire on
clinical consequences, underwent chest CTand 18F-FDG PET/CT, and provided
blood samples on the same day. Forty-five volunteers served as control subjects.
Analysis of CTimages and quantitative voxel-based analysis of PET/CTimages
were performed for both groups. 18F-FDGuptake in thewhole-lung volume and
in high- and low-attenuation areaswas calculated and normalized to liver values.
Quantification of plasma markers of inflammation (interleukin 6), D-dimer, and
endothelial cell activation (angiopoietins 1 and 2, vascular cell adhesion molecule
1, and intercellular adhesion molecule 1) was also performed.
Results: We enrolled 53 COVID-19 survivors (62.3% were male; median age,
50 years). All survivors reported at least 1 persistent symptom, and 41.5% reported
more than 6 symptoms. The mean lung density was greater in survivors
than in control subjects, and more metabolic activity was observed in normal
and dense lung areas, even months after symptom onset. Plasma proinflammatory proinflammatory,
coagulation, and endothelial activation biomarker concentrations were also
significantly higher in survivors.
Conclusion:We observed more metabolic activity in areas of high and normal
lung attenuation several months after moderate to severe COVID-19 pneumonia.
In addition, plasma markers of thromboinflammation and endothelial activation
persisted. These findings may have implications for our understanding
of the in vivo pathogenesis and long-lasting effects of COVID-19 pneumonia. | |
dc.format | application/pdf | |
dc.language | eng | |
dc.publisher | Wolters Kluwer Health, Inc | |
dc.rights | open access | |
dc.subject | COVID-19 | |
dc.subject | Pneumonia | |
dc.subject | Ativação de células endoteliais | |
dc.subject | Imunometabolismo | |
dc.subject | COVID longa | |
dc.subject | PET/CT | |
dc.subject | Inflamação pulmonar | |
dc.subject | COVID-19 | |
dc.subject | Pneumonia | |
dc.subject | Endothelial cell activation | |
dc.subject | Immunometabolism | |
dc.subject | long COVID | |
dc.subject | PET/CT | |
dc.subject | Pulmonary inflammation | |
dc.title | Increased Lung Immune Metabolic Activity in COVID-19 Survivors | |
dc.type | Article | |